671
edits
Swallow Syncope: Difference between revisions
Jump to navigation
Jump to search
no edit summary
Jelledejong (talk | contribs) No edit summary |
Jelledejong (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
Swallow syncope incorporates two separate conditions: | Swallow syncope incorporates two separate conditions: | ||
# a pharyngeal form which is usually associated with pain (“syncopal glossopharyneal neuralgia”) | # a pharyngeal form which is usually associated with pain (“syncopal glossopharyneal neuralgia”) | ||
# an oesophageal variety, also known as “oesophageal” or “deglutition syncope” (fig. 7) | # an oesophageal variety, also known as “oesophageal” or “deglutition syncope” (fig. 7)<cite>Basker</cite>. | ||
The first isolated case description dates to 1906 (Mackenzie, 1906). Based on the fact that up to date there are only about sixty single cases reported (DEUCHAR & TROUNCE, 1960;Basker & Cooper, 2000), swallow syncope is probably rare. | The first isolated case description dates to 1906 (Mackenzie, 1906). Based on the fact that up to date there are only about sixty single cases reported (DEUCHAR & TROUNCE, 1960;Basker & Cooper, 2000), swallow syncope is probably rare. | ||
| Line 19: | Line 19: | ||
# Secondly, if feasible, modification of antihypertensive drugs should be considered. | # Secondly, if feasible, modification of antihypertensive drugs should be considered. | ||
Surgical or pharmacological destruction of (the oesophageal branches of) the vagus nerve has shown not to be successful. Based on predominantly positive therapeutic response in over a dozen cases, the treatment of choice of oesophageal syncope is insertion of a cardiac demand pacemaker (Basker & Cooper, 2000). Management of persisting neuralgia is symptomatic. | Surgical or pharmacological destruction of (the oesophageal branches of) the vagus nerve has shown not to be successful. Based on predominantly positive therapeutic response in over a dozen cases, the treatment of choice of oesophageal syncope is insertion of a cardiac demand pacemaker (Basker & Cooper, 2000). Management of persisting neuralgia is symptomatic. | ||
==References== | |||
<biblio> | |||
#Basker pmid=10932658 | |||
</biblio> | |||